regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Pharmacokinetics === Information about pharmacokinetics and pharmacodynamics of DNP in humans is limited. DNP is metabolized via nitro reduction. Its major metabolites are 2-amino-4-nitrophenol and 4-amino-2-nitrophenol. In overdoses, symptom onset can be as soon as 3 hours and the average time to death was 14 hours.
=== Antibiotic === Honey has long been used as a topical antibiotic by practitioners of traditional and herbal medicine. Honey's antibacterial effects were first demonstrated by the Dutch scientist Bernardus Adrianus van Ketel in 1892. Since then, numerous studies have shown that honey has broad-spectrum antibacterial activity against gram-positive and gram-negative bacteria, although potency varies widely between different honeys. Due to the proliferation of antibiotic-resistant bacteria in the last few decades, there has been renewed interest in researching the antibacterial properties of honey. Components of honey under preliminary research for potential antibiotic use include methylglyoxal, hydrogen peroxide, and royalisin (also called defensin-1).
== History == Historical and archaeological evidence suggests that mastiffs have long been distinct in both form and function from the similarly large livestock guardian dogs from which they were most likely developed; they also form separate genetic populations. The Fédération Cynologique Internationale and some kennel clubs group the two types together as molossoid dogs; some modern livestock guardian breeds, such as the Pyrenean Mastiff, the Spanish Mastiff and the Tibetan Mastiff, and an extinct draught dog called the Belgian Mastiff, have the word "mastiff" in their name, but are not considered true mastiffs. Many older English sources refer to mastiffs as bandogs or bandogges, although technically the term "bandog" meant a dog that was tethered by a chain (or "bande") that would be released at night; the terms "mastiff" and "bandog" were often used interchangeably. In the twentieth century the term "bandog" was revived to describe some large fighting mastiff type dogs crossed with any bulldog in the United States.
Sources: en.wikipedia.org
=== Pharmacological regulation === In certain conditions such as in the case of cardiac disease, the Na+/K+-ATPase may need to be inhibited via pharmacological means. A commonly used inhibitor used in the treatment of cardiac disease is digoxin (a cardiac glycoside) which essentially binds "to the extracellular part of enzyme i.e. that binds potassium, when it is in a phosphorylated state, to transfer potassium inside the cell" After this essential binding occurs, a dephosphorylation of the alpha subunit occurs which reduces the effect of cardiac disease. It is via the inhibiting of the Na+/K+-ATPase that sodium levels will begin to increase within the cell which ultimately increases the concentration of intracellular calcium via the sodium-calcium exchanger. This increased presence of calcium is what allows for the force of contraction to be increased. In the case of patients where the heart is not pumping hard enough to provide what is needed for the body, use of digoxin helps to temporarily overcome this.
== Chemical Modifications == The general purpose of HA modifications is to improve certain properties such as biocompatibility, permeation, and sustained drug release. It can also be modified to test the functionality of certain groups, such as the carboxyl or hydroxyl groups. These improvements to HA are achieved through cross-linking and bioconjugation with various molecules, such as acid derivatives, ketones, aldehydes, biopolymers, and probes. There are three sites on HA that can be modified: the Carboxylic acid group (COOH), the hydroxyl group (OH), and the N-acetyl group (NHCOH3). Modifications of the carboxylic acid group include amidation, Ugi condensation, and ester formation. Modifications of the hydroxyl group include ether formation, hemiacetal formation, ester formation, carbamate formation, and oxidation with sodium periodate. Modifications of the N-acetyl group include deacetylation, followed by amidation or Ugi condensation.
Muscle glycogen appears to function as a reserve of quickly available phosphorylated glucose, in the form of glucose-1-phosphate, for muscle cells. Glycogen contained within skeletal muscle cells are primarily in the form of β particles. Other cells that contain small amounts use it locally as well. As muscle cells lack glucose-6-phosphatase, which is required to pass glucose into the blood, the glycogen they store is available solely for internal use and is not shared with other cells. This is in contrast to liver cells, which, on demand, readily do break down their stored glycogen into glucose and send it through the blood stream as fuel for other organs. Skeletal muscle needs ATP (provides energy) for muscle contraction and relaxation. Skeletal muscle relies predominantly on glycogenolysis for the first few minutes as it transitions from rest to activity, as well as throughout high-intensity aerobic activity and all anaerobic activity. During anaerobic activity, such as weightlifting and isometric exercise, the phosphagen system (ATP-PCr) and muscle glycogen are the only substrates used as they do not require oxygen nor blood flow. Different bioenergetic systems produce ATP at different speeds, with ATP produced from muscle glycogen being much faster than fatty acid oxidation. The level of exercise intensity determines how much of which substrate (fuel) is used for ATP synthesis also. Muscle glycogen can supply a much higher rate of substrate for ATP synthesis than blood glucose.
== Broadcast == Matlock premiered with a sneak peek on September 22, 2024, before its timeslot premiere on October 17 on CBS. In Canada, the series airs on Global and is available to stream on StackTV. The second season premiered on October 12, 2025. In Australia, the show premiered on Channel Ten on the November 11, 2024 and has continued to air its second season through January 2026 and also airs on Paramount+. In Croatia, the show premiered on national HRT 1 starting with the first season on the 15th. June 2026.
Sources: en.wikipedia.org
In 2021, GNC launched their Venture Capital Arm under the name GNC Ventures. Led by COO Nate Frazier's investment in Real Eats. Additional investments include supplement brands, POS and OMS software companies. In 2023, COO Nate Frazier unveiled GNC's Flagship in the heart of Pittsburgh. Starting with significant upgrades into the brand's tech stack. A major part of that was updating point-of-sale systems to allow for more in-store ordering, plus functions like loyalty programs. The newest version of the system also allows store associates to be able to sell outside of the store – such as going to a marathon, community event or parking lot tailgate, by utilizing mobile point-of-sale systems. In May 2025, U.S. representative Pat Harrigan introduced legislation that would prohibit GNC's presence on U.S. military bases due to its Harbin ownership.
Following the possibility of nicotine addiction from e-cigarette use, there is also concern children may start smoking traditional cigarettes in greater numbers as well, as youth who use e-cigarettes are more likely to go on to smoke cigarettes. Their part in tobacco harm reduction is unclear, while another review found they appear to have the potential to lower tobacco-related death and disease. Regulated US Food and Drug Administration nicotine replacement products may be safer than e-cigarettes, but e-cigarettes are generally seen as safer than combusted tobacco products. It is estimated their safety risk to users is similar to that of smokeless tobacco. The long-term effects of e-cigarette use are unknown. The risk from serious adverse events was reported in 2016 to be low. Less serious adverse effects include abdominal pain, headache, blurry vision, throat and mouth irritation, vomiting, nausea, and coughing. Nicotine itself is associated with some health harms. In 2019 and 2020, an outbreak of severe lung illness throughout the US was linked to the use of vaping products. E-cigarettes create vapor made of fine and ultrafine particles of particulate matter, which have been found to contain propylene glycol, glycerin, nicotine, flavors, small amounts of toxicants, carcinogens, and heavy metals, as well as metal nanoparticles, and other substances. Its exact composition varies across and within manufacturers, and depends on the contents of the liquid, the physical and electrical design of the device, and user behavior, among other factors.
== Further reading == Craigie, W.A.; Bradley, H. (1914). "Realgar". In Sir James, A.H. Murray (ed.). A New English Dictionary on Historical Principles. Clarendon Press at Oxford. p. 202 – via archive.org. William Mesny (1899). Mesny's Chinese Miscellany. A Text Book of Notes on China and the Chinese. Vol. III. Shanghai. p. 251. William Mesny (1905). Mesny's Chinese Miscellany. A Text Book of Notes on China and the Chinese. Vol. IV. Shanghai. pp. 425–426.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.